Nrf2在肿瘤发生发展中的“双刃剑”作用  

The"double-edged sword"effect of Nrf2 in tumor genesis and development

作　　者：肖若曦 王莎莎[1] 丁爱萍[1] 张渝琪 刘钊[1] 邱文生[1] XIAO Ruoxi;WANG Shasha;DING Aiping;ZHANG Yuqi;LIU Zhao;QIU Wensheng(Department of Oncology,the Affiliated Hospital of Qingdao University,Shandong Qingdao 266011,China)

机构地区：[1]青岛大学附属医院肿瘤内科,山东青岛266011

出　　处：《现代肿瘤医学》2021年第18期3308-3311,共4页Journal of Modern Oncology

基　　金：北京希思科临床肿瘤学研究基金会(编号:Y-XD 2019-119,Y-HR2018-185);吴阶平医学基金会(编号:320.6750.2020-12-19)。

摘　　要：核因子E2相关因子2(Nrf2)是调控抗氧化应激反应过程中的关键转录因子,在保护正常细胞免受活性氧诱导DNA损伤的同时,恶性肿瘤细胞也受到保护。因此,Nrf2在肿瘤的发生与发展中有着双重作用。研究表明,Nrf2在正常组织中可抑制肿瘤形成,而在肿瘤组织中Nrf2引发的保护性反应可为特定肿瘤组织提供生长优势。本文将就Nrf2对肿瘤发生发展及化疗耐药的影响、Nrf2相关的抗肿瘤治疗三方面进行综述,为抗肿瘤药物靶点的选择提供理论依据。Nuclear factor E2-related factor 2(Nrf2)is a key transcription factor in the regulation of antioxidant response,while Nrf2 protects healthy cells from ROS-induced DNA damage,malignant tumor cells are also protected.Therefore Nrf2 plays a dual role in the occurrence and development of tumors.It has been shown that Nrf2 can inhibit the formation of tumor tissues in normal,while the protective response induced by Nrf2 in tumor tissues may provide growth advantages in specific cancers.This review summarizes the role of Nrf2 in tumor development,chemotherapy resistance and anti-tumor treatment related to Nrf2,and provides a theoretical basis for the selection of antitumor drug targets.

关 键 词：核因子E2相关因子2(Nrf2) Kelch样ECH相关蛋白1(Keap1) 双重作用 耐药性 抗肿瘤治疗 

分 类 号：R730.5[医药卫生—肿瘤]